Invex Therapeutics climbs on progress in drug development for European market

Invex Therapeutics

23/12/2020 24:56

** Invex Therapeutics Ltd  IXC.AX  rises as much as 11.1% to
A$0.700, on track for its biggest gain since Nov. 20
    ** The biopharmaceutical company concludes protocol
assistance process with the European Medicines Agency regarding
co's clinical development plan for Presendin, its intracranial
hypertension treatment  urn:newsml:reuters.com:*:nASXcnsBl
    ** IXC says receipt of further protocol assistance from EMA
provides it with sufficient regulatory input to complete the
design of a single Phase III trial to support market approval
for Presendin in Europe
    ** More than 424,000 shares change hands, compared with the
30-day average volume of about 214,000
    ** Stock down 26.7% this year, as of last close

 (Reporting by Rashmi Ashok in Bengaluru)
 ((Rashmi.Ashok@thomsonreuters.com; +918061822604;))